Effect of Repetitive Transcranial Magnetic Stimulation on Resting State Brain Activity in Schizophrenia
Status
Conditions
Treatments
Details and patient eligibility
About
This study compares the efficacy of low and high frequency repetitive transcranial magnetic stimulation (rTMS) as a means of treating subjects with schizophrenia. Magnetic pulses delivered over the scalp cause brain activity. This activity has been shown to help decrease the intensity and frequency of auditory hallucinations (AH) in schizophrenia. The investigators will compare whether low or high frequencies work best. The investigators will also examine what changes occur in the brain that are related to improvement.
Full description
Background. The sub-Investigator Dr. Mennemeier has been using repetitive transcranial magnetic stimulation (rTMS) to treat phantom sound perception in subjects with tinnitus. The Principal Investigator (PI), Dr. Messias, now aims to team up with Drs. Mennemeier and James, to learn how rTMS influences phantom sound perception in schizophrenia. rTMS has already been shown to be an effective treatment for both tinnitus and schizophrenia. rTMS is a non-invasive method of regional brain stimulation that can significantly reduce phantom sound perception temporarily in 50% of subjects with tinnitus and schizophrenia. This study will go further than previous investigations by analyzing how different frequencies of rTMS influence not only auditory hallucinations (AH) in schizophrenia but also brain connectivity in schizophrenia. The investigators want to learn if rTMS decreases AH by normalizing brain connectivity. Whereas this study focuses on schizophrenic subjects with AH, the design is very similar to ongoing work on tinnitus so the findings will be comparable.
Tinnitus and AH in schizophrenia are prevalent and disabling disorders of sound perception. The investigators understanding of the precise mechanisms of these disorders is lacking. Interestingly, the symptoms of both disorders respond positively to rTMS of the temporal cortex in ways that defy contemporary understanding of the nature of these symptoms and of how rTMS should work to improve them. For example, phantom sound perception in both tinnitus and schizophrenia are linked to maladaptive, hyperactivity of auditory processing regions of temporal cortex; however, it is increasingly clear that these pathological changes alone are insufficient to explain the pronounced intrusiveness and negative emotional valance of symptoms in each disorder. Therefore, a barrier to understanding these disorders lies in understanding how changes in auditory cortex are synchronized with changes in other cortical regions that regulate perception and emotion. Additionally, at present, the decision of which rTMS frequency to apply as a treatment for phantom sound perception has no firm theoretical or empirical basis. Whereas, low frequency rTMS has traditionally been used, based upon contemporary models, to "inhibit" hyperactivity in auditory cortex; high frequency rTMS, which should induce an opposite effect on neuronal processing, not only works to improve symptoms but may be more effective for some subjects than low frequency rTMS. Therefore, contemporary models designed to explain how the frequency of rTMS influences neuronal activity immediate following stimulation are insufficient to explain how low and high frequencies of rTMS can mitigate phantom sound perception for days, weeks and months following a single course of treatment.
Hypothesis. The investigators propose that phantom sound perception in schizophrenia result from an imbalance of excitatory and inhibitory neural process in auditory networks and from synchronized, maladaptive changes in linked brain regions that regulate perception and emotion. Treating auditory cortex with repetitive, external magnetic stimulation can decrease phantom sound perception and distress by reversing the maladaptive brain reorganization that is set in motion by these underlying neural imbalances.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
-
Inclusion Criteria for schizophrenic subjects.
- Male and female patients, 21-65 years of age, of all races and ethnicities
- Diagnosis of auditory hallucinations (AH) associated with schizophrenia (verified at screening)
- Must report experiencing the presence of their phantom auditory perception for at least 6 months
- Female Subjects of childbearing age must take a pregnancy test to rule out pregnancy prior to participating in this study and during the study.
- Willing to provide informed consent to participate in all study interventions and assessments
- Subjects must have the capacity to sign and informed consent or a legal authorized representative (LAR) must sign in addition to the subject.
-
Inclusion Criteria for control subjects.
- Male and female patients, 21-65 years of age, of all races and ethnicities
- Willing to provide informed consent to participate in all study interventions and assessments
Exclusion criteria
-
Exclusion Criteria for schizophrenic subjects:
-
Subjects with significant neurological disease, acoustic neuromas or glomus tumors, or other contraindicated neuropathology.
-
Claustrophobia, or the inability to lie still in a confined space
-
Additional exclusion criteria for repetitive Transcranial Magnetic Stimulation (rTMS) include the following:
- a personal or family history of epilepsy;
- a personal history of head injury, aneurysm, stroke, previous cranial neurosurgery, neurological or psychiatric disorders other than schizophrenia, or migraines
- recent use of cocaine or alcohol
- metal implants in the head or neck
- a pacemaker
- pregnancy (or the possibility of pregnancy)
- medications that lower seizure threshold (tricyclic antidepressants or bupropion) or reduce cortical excitation (anticonvulsants or benzodiazepines).
-
Persons under 21 years of age (children) are excluded because the effect of rTMS on children is unknown, in contrast to adults, who have been well studied.
-
Exclusion items specific to Functional Magnetic Resonance Imaging (fMRI):
- magnetic metallic implants
- electronic or magnetic implants, such as pacemakers, as these may stop working
- nonremovable dental implants
- permanent makeup or tattoos with metallic dyes
- a positive pregnancy test (for females)
- a self-reported history of loss of consciousness greater than 10 minutes
- physical disabilities that prohibit task performance
-
Any other condition that the investigator believes might put the participant at risk
-
-
Exclusion Criteria for control subjects:
- Subjects with significant neurological disease, acoustic neuromas or glomus tumors, or other contraindicated neuropathology.
- Claustrophobia, or the inability to lie still in a confined space
- Magnetic metallic implants
- Electronic or magnetic implants, such as pacemakers, as these may stop working
- Nonremovable dental implants
- Permanent makeup or tattoos with metallic dyes
- A positive pregnancy test (for females)
- A self-reported history of loss of consciousness greater than 10 minutes
- Physical disabilities that prohibit task performance
- Any other condition that the investigator believes might put the participant at risk
Trial design
Primary purpose
Allocation
Interventional model
Masking
26 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal